UB Paderborn / Katalog / Suche / in CDI

Spirocyclic Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-3-hydroxy-4-(spiro[chromene-2,4′-piperidine]-4-yl) Benzamide (ADL5747)

Journal of medicinal chemistry, 2009-09, Vol.52 (18), p.5685-5702

2009

Link zum Volltext

Verfügbarkeit prüfen

Mu Opioid Receptor Antagonists: Recent Developments

ChemMedChem, 2007-11, Vol.2 (11), p.1552-1570

2007

Link zum Volltext

Verfügbarkeit prüfen

Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity

Cell reports (Cambridge), 2018-12, Vol.25 (10), p.2742-2754.e31

2018

Link zum Volltext

Verfügbarkeit prüfen

Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease

Molecular neurobiology, 2022-04, Vol.59 (4), p.2171-2189

2022

Link zum Volltext

Verfügbarkeit prüfen

The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

Movement disorders, 2011-06, Vol.26 (7), p.1225-1233

2011

Link zum Volltext

Verfügbarkeit prüfen

Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates

Current medicinal chemistry, 2009-08, Vol.16 (24), p.3093

2009

Link zum Volltext

Verfügbarkeit prüfen

Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists

Bioorganic & medicinal chemistry letters, 2009-10, Vol.19 (20), p.5931-5935

2009

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2009

Journal of combinatorial chemistry, 2010-11, Vol.12 (6), p.765-806

2010

Link zum Volltext

Verfügbarkeit prüfen

Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability

Bioorganic & medicinal chemistry letters, 2010, Vol.20 (1), p.387-391

2010

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT1 Angiotensin II Receptor Antagonists

Journal of medicinal chemistry, 2000-07, Vol.43 (14), p.2685-2697

2000

Link zum Volltext

Verfügbarkeit prüfen

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128928-128928, Article 128928

2022

Link zum Volltext

Verfügbarkeit prüfen

CB2 selective sulfamoyl benzamides : Optimization of the amide functionality

Bioorganic & medicinal chemistry letters, 2009-01, Vol.19 (2), p.309-313

2009

Link zum Volltext

Verfügbarkeit prüfen

δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization

The Journal of pharmacology and experimental therapeutics, 2012-09, Vol.342 (3), p.799

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128929-128929, Article 128929

2022

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a series of aminopiperidines as novel iNOS inhibitors

Bioorganic & medicinal chemistry, 2008, Vol.18 (1), p.336-343

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1640: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1640-1640

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4938: DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4938-4938

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1639: DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1639-1639

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4033-4033

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1613: Dimerization-induced activation of the integrated stress response kinase PERK by an investigational small molecule modulator, DP-9024

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1613-1613

2023

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2007

Journal of combinatorial chemistry, 2008-11, Vol.10 (6), p.753-802

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4045-4045

2023

Link zum Volltext

Verfügbarkeit prüfen

General and efficient synthetic approach to novel tricyclic spiroketones

Tetrahedron, 2009-07, Vol.65 (27), p.5161-5167

2009

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Pharmacological Evaluation of Novel Octahydro-1H-pyrido[1,2-a]pyrazine as μ-Opioid Receptor Antagonists

Journal of medicinal chemistry, 2006-12, Vol.49 (25), p.7290-7306

2006

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Spirocyclic Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-3-hydroxy-4-(spiro[chromene-2,4′-piperidine]-4-yl) Benzamide (ADL5747)

Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

Mu Opioid Receptor Antagonists: Recent Developments

Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity

Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease

The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates

Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists

Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2009

Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability

Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT1 Angiotensin II Receptor Antagonists

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

CB2 selective sulfamoyl benzamides : Optimization of the amide functionality

δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Discovery of a series of aminopiperidines as novel iNOS inhibitors

Abstract 1640: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents

Abstract 4938: DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors

Abstract 1639: DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

Abstract 1613: Dimerization-induced activation of the integrated stress response kinase PERK by an investigational small molecule modulator, DP-9024

Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2007

Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models

General and efficient synthetic approach to novel tricyclic spiroketones

Synthesis and Pharmacological Evaluation of Novel Octahydro-1H-pyrido[1,2-a]pyrazine as μ-Opioid Receptor Antagonists

Suchergebnisse filtern